MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
19.69
-0.94
-4.56%
After Hours: 19.92 +0.23 +1.17% 18:12 02/20 EST
OPEN
20.64
PREV CLOSE
20.63
HIGH
20.71
LOW
19.68
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
22.73
52 WEEK LOW
8.58
MARKET CAP
1.71B
P/E (TTM)
-5.4611
1D
5D
1M
3M
1Y
5Y
1D
Syndax Pharmaceuticals Inc. published an update to their financial calendar
Reuters · 3d ago
How Revuforj’s Global Access Push At Syndax Pharmaceuticals (SNDX) Has Changed Its Investment Story
Simply Wall St · 5d ago
Weekly Report: what happened at SNDX last week (0209-0213)?
Weekly Report · 6d ago
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Revuforj Data And New Managed Access Program
Simply Wall St · 02/15 05:26
Have Insiders Sold Syndax Pharmaceuticals Shares Recently?
Simply Wall St · 02/13 10:11
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
Seeking Alpha · 02/12 10:44
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After A 46% One Year Share Price Gain?
Simply Wall St · 02/12 08:33
Top Syndax Insiders Quietly Cash Out in Eye-Catching Stock Moves
TipRanks · 02/11 02:07
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.